On January 5, 2022, Mark Levin notified the Fulcrum Therapeutics, Inc. of his decision to resign as a member of the Board of Directors of the Company, effective April 18, 2022. With the resignation, Mr. Levin will also resign as a member of the Company's Nominating and Corporate Governance Committee and Science and Technology Committee. Mr. Levin's resignation was not due to any disagreement with the Company on any matter relating to the Company's operations, policies or practices.

On January 10, 2022, the Company announced that Kate Haviland has been named Chair of the Board. Mr. Levin has ceased to serve as Executive Chairman of the Company and will remain on the Board until the effective date of his resignation.